Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00470470
Recruitment Status : Completed
First Posted : May 7, 2007
Results First Posted : December 23, 2014
Last Update Posted : December 23, 2014
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease Intervention/treatment Phase
Acral Lentiginous Malignant Melanoma Recurrent Melanoma Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma Drug: imatinib mesylate Other: laboratory biomarker analysis Phase 2

Detailed Description:


I. Determine the overall objective response rate (complete response and partial response) in patients with inoperable stage III or IV melanoma harboring somatic alterations in c-KIT treated with imatinib mesylate.


I. Determine the time to progression in patients treated with this drug. II. Determine if c-KIT mutational status by DNA sequencing, DNA copy number status by fluorescent in situ hybridization (FISH) or comparative genomic hybridization, and/or protein expression by immunohistochemistry (IHC) can best predict clinical benefit from imatinib mesylate.


I. To evaluate tumors resistant to small molecule inhibitors of Kit for the development of secondary Kit mutations or for changes in Kit copy number.

II. To evaluate for changes in Ki-67, phospho-Akt, phospho-MEK, phospho-S6, phospho STAT3, cleaved caspase 3, IGF-1R, and Kit expression in paired tumor samples obtained from patients treated with a small molecule inhibitor of Kit.

III. To analyze baseline and post-resistance blood samples for soluble cKIT levels, soluble VEGFR1, soluble VEGFR2, VEGF, PlGF, FGF, and melanoma inhibitory activity (MIA) levels, and circulating tumor cells.

IV. To analyze concomitant samples of blood and tumor for imatinib levels in patients treated with imatinib.

OUTLINE: This is a multi-center study. Patients are stratified according to true amplification of c-KIT by FISH vs mutations by DNA sequencing.

Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.

Tumor tissue samples or unstained tissue slides/paraffin blocks may be collected. c-KIT is evaluated by IHC and comparative genomic hybridization.

After completion of study treatment, patients are followed up periodically.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT
Study Start Date : April 2007
Actual Primary Completion Date : December 2013
Actual Study Completion Date : October 2014

Arm Intervention/treatment
Experimental: Treatment (enzyme inhibitor therapy)
Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
Drug: imatinib mesylate
Given orally
Other Names:
  • CGP 57148
  • Gleevec
  • Glivec

Other: laboratory biomarker analysis
Correlative studies

Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: Every 6 weeks for the first 3 courses and then every 12 weeks thereafter ]
    Response will be evaluated in this study using the new international criteria proposed by the RECIST Committee. A Simon two-stage minimax design will be employed.

Secondary Outcome Measures :
  1. Time to Progression [ Time Frame: Time from the treatment start to the date of disease progression ]
    Progression will be evaluated in this study using the new international criteria proposed by the RECIST Committee. Time to progression will be estimated using the Kaplan-Meier method.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed inoperable stage III or IV melanoma that began on acral skin or mucosa

    • Patients with cutaneous melanoma that began on sun exposed sites of the skin and whose pathology demonstrates signs of sun damage (solar elastosis) involving the skin surrounding their primary melanoma are eligible
  • Must have sufficient tumor tissue available for FISH and DNA sequencing

    • Patients must have either a true amplification of 4q12 or a detectable mutation of c-KIT
    • If no banked tumor tissue is available, or if the available banked tumor tissue is insufficient for the necessary testing, then a repeat biopsy procedure will be required to collect the necessary tumor sample
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
  • No known untreated brain or epidural metastases

    • Brain metastases that have been treated and deemed stable are allowed
  • ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
  • Life expectancy greater than 3 months
  • WBC ≥ 3,000/mm³
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)

    • Patients with unexplained hyperbilirubinemia that is clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert's syndrome) may be eligible
  • AST and ALT ≤ 2.5 times ULN (5 times ULN if hepatic metastases are present)
  • Creatinine ≤ 1.5 times ULN
  • PT and PTT ≤ 1.5 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception before and during study participation
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to imatinib mesylate
  • No concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable anginapectoris
    • Cardiac arrhythmia resulting in hemodynamic instability
    • Intestinal malabsorption disorders
    • Psychiatric illness or social situations that would limit study compliance
  • Recovered to grade 1 from all prior therapies with the exception of alopecia
  • At least 2 weeks since prior radiotherapy (≤ 3,000 cGy to fields including substantial marrow)
  • At least 2 weeks since prior isolated limb infusion or perfusion (must have evidence of progression despite this therapy)
  • At least 2 weeks since prior chemotherapy
  • No more than 2 prior chemotherapy regimen for metastatic melanoma
  • Prior therapies with vaccines, targeted agents not believed to affect the kit proteins, cytokines, interferon-α, or intratumoral injections will NOT be considered prior therapy unless administered with a chemotherapy drug
  • No prior therapy with an inhibitor of the kit protein
  • No other concurrent investigational agents
  • No other concurrent anticancer agents or therapies
  • No concurrent antiretroviral therapy for HIV-positive patients
  • No concurrent inhibitors of CYP3A4, including any of the following:

    • Fluconazole, itraconazole, ketoconazole, macrolide antibiotics (azithromycin, clarithromycin, erythromycin, troleandomycin),midazolam, nifedipine, verapamil, diltiazem, terfenadine, cyclosporine and cisapride
    • Herbal extracts and tinctures with CYP3A4 inhibitory activity, including the following:

      • Hydrastis canadensis (goldenseal), Hypericum perforatum (St. John's wort),Uncaria tomentosa (cat's claw), Echinacea angustifolia roots, Trifolium pratense(wild cherry), Matricaria, chamomilla (chamomile), Glycyrrhiza glabra (licorice), dillapiol, hypericin, and naringenin
  • No concurrent inducers of CYP3A4, including any of the following:

    • Carbamazepine, phenobarbital, phenytoin, and rifampin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00470470

Layout table for location information
United States, California
University of California at Los Angeles (UCLA )
Los Angeles, California, United States, 90095
United States, Florida
Mount Sinai Medical Center CCOP
Miami Beach, Florida, United States, 33140
Good Samaritan Medical Center
West Palm Beach, Florida, United States, 33401
Palm Beach Cancer Institute-Main Office
West Palm Beach, Florida, United States, 33401
United States, New York
New York University Langone Medical Center
New York, New York, United States, 10016
Mount Sinai Medical Center
New York, New York, United States, 10029
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Weill Medical College of Cornell University
New York, New York, United States, 10065
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Richard Carvajal Memorial Sloan Kettering Cancer Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00470470    
Other Study ID Numbers: NCI-2009-00216
NCI-2009-00216 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
07-014 ( Other Identifier: Memorial Sloan-Kettering Cancer Center )
7754 ( Other Identifier: CTEP )
P30CA008748 ( U.S. NIH Grant/Contract )
N01CM62206 ( U.S. NIH Grant/Contract )
N01CM62204 ( U.S. NIH Grant/Contract )
First Posted: May 7, 2007    Key Record Dates
Results First Posted: December 23, 2014
Last Update Posted: December 23, 2014
Last Verified: January 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action